Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem and Faropenem EBA in Pulmonary Tuberculosis
NCT02349841Phase 2Completed
- Sponsor
- TASK Foundation
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of meropenem, faropenem in pulmonary tuberculosis (TB), sponsored by TASK Foundation. Started Sep 2014; status: completed.
02
Drugs
meropenemfaropenem
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02349841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349841.